Roche's Tecentriq Intravenous Cancer Therapy Gets UK Approval
29 8월 2023 - 6:51PM
Dow Jones News
By Giulia Petroni
Roche said the U.K.'s medicines regulator has approved its
Tecentriq intravenous cancer therapy.
The Swiss pharmaceutical company said Tuesday that the therapy
will be available to patients for all indications in which the
formulation has been previously approved, including certain types
of lung, bladder, breast and liver cancer.
Tecentriq SC is Roche's fourth subcutaneous cancer therapy.
The approval granted by the U.K. Medicines and Healthcare
products Regulatory Agency is the first for Tecentriq SC globally.
Evaluations by the U.S. Food and Drug Administration and other
health authorities are currently underway, Roche said.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
August 29, 2023 05:36 ET (09:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Roche (QX) (USOTC:RHHBY)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Roche Holdings Ltd AG (QX) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Roche Holdings Ltd AG (QX) News Articles